HOB Biotech Group Corp.,Ltd

Shanghai Stock Exchange 688656.SS

HOB Biotech Group Corp.,Ltd Price to Sales Ratio (P/S) on January 14, 2025: 13.22

HOB Biotech Group Corp.,Ltd Price to Sales Ratio (P/S) is 13.22 on January 14, 2025, a 142.74% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

HOB Biotech Group Corp.,Ltd 52-week high Price to Sales Ratio (P/S) is 23.20 on November 25, 2024, which is 75.42% above the current Price to Sales Ratio (P/S).
HOB Biotech Group Corp.,Ltd 52-week low Price to Sales Ratio (P/S) is 3.13 on February 07, 2024, which is -76.31% below the current Price to Sales Ratio (P/S).
HOB Biotech Group Corp.,Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 6.70.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 688656.SS

HOB Biotech Group Corp.,Ltd

CEO	Mr. John Li
IPO Date	Jan. 13, 2021
Location	China
Headquarters	C10 Building
Employees	550
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, China.

Key trends

Past 5 years